Supported by the FEMHabil Program, Faculty of Medicine, University of Bonn to M.S. This project has also received funding from the Innovative Medicines Initiative (IMI) 2 Joint Undertaking under grant agreement No. 116076. This Joint Undertaking receives support from the European Union's Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Supported in part by an Unrestricted Grant from Research to Prevent Blindness, New York, NY, to the Department of Ophthalmology & Visual Sciences, University of Utah.
MACUSTAR Consortium Members: H. Agostini, I. Aires, L. Altay, R. Atia, F. Bandello, P. G. Basile, J. Batuca, C. Behning, M. Belmouhand, M. Berger, A. Binns, C. J. F. Boon, M. Böttger, A. R. Branco, J. E. Brazier, C. Carapezzi, J. Carlton, A. Carneiro, A. Charil, R. Coimbra, D. Cosette, M. Cozzi, D. P. Crabb, J. Cunha-Vaz, C. Dahlke, H. Dunbar, R. P. Finger, E. Fletcher, M. Gutfleisch, F. Hartgers, B. Higgins, J. Hildebrandt, E. Höck, R. Hogg, F. G. Holz, C. B. Hoyng, A. Kilani, J. Krätzschmar, L. Kühlewein, M. Larsen, S. Leal, Y. T. E. Lechanteur, D. Lu, U. F. O. Luhmann, A. Lüning, N. Manivannan, I. Marques, C. Martinho, K. P. Moll, G. Montesano, Z. Mulyukov, M. Paques, B. Parodi, M. Parravano, S. Penas, T. Peters, T. Peto, S. Poor, S. Priglinger, R. Ramamirtham, D. Rowen, G. S. Rubin, J. Sahel, C. Sánchez, O. Sander, M. Saßmannshausen, M. Schmid, S. Schmitz-Valckenberg, J. Siedlecki, R. Silva, E. Souied, G. Staurenghi, J. Tavares, D. J. Taylor, J. H. Terheyden, A. Tufail, P. Valmaggia, M. Varano, A. Wolf, and N. Zakaria.
Disclaimer: The communication reflects the authors' views. Neither IMI nor the European Union, EFPIA, or any associated partners are responsible for any use that may be made of the information contained therein.
Disclosure: C. de Vente, Novartis (F); P. Valmaggia, Heidelberg Engineering (R), Bayer (R); C.B. Hoyng, None; F.G. Holz, Acucela (C, F), Allergan (F), Apellis (C, F), Bayer (C, F), Boehringer-Ingelheim (C), Bioeq/Formycon (F, C), CenterVue (F), Ellex (F), Roche/Genentech (C, F), Geuder (C, F), Graybug (C), Gyroscope (C), Heidelberg Engineering (C, F), IvericBio (C, F), Kanghong (C, F), LinBioscience (C), NightStarX (F), Novartis (C, F), Optos (F), Oxurion (C), Pixium Vision (C, F), Oxurion (C), Stealth BioTherapeutics (C), Zeiss (F, C); GRADE Reading Center (O); M.M. Islam, None; C.C.W. Klaver, None; C.J.F. Boon, None; S. Schmitz-Valckenberg, AlphaRET (C), Apellis (C, R), Bayer (F), Fomycon (C), Carl Zeiss MediTec (F), Galimedix (C), Heidelberg Engineering (F, R), Katairo (C), Kubota Vision (C), Novartis (C, F), Perceive Therapeutics (C), Pixium (C), Roche (C, F), SparingVision (C); A. Tufail, Annexon, Apellis, Astellas, Bayer, Astellas, Boehringer-Ingelheim, 4D Molecular Therapeutics, Graybug, Heidelberg Engineering, IvericBio/Astellas, Janssen, Novartis, Ocular Therapeutix, Oxurion Roche, Zeiss; M. Saßmannshausen, Heidelberg Engineering (F), Optos (F), Zeiss, CenterVue (F); C.I. Sánchez, Novartis (F), Novartis (R), Bayer (R)